RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I think I previously posted that I see the upfront potential to be less now. Rumors were of $30-50 million at that time, I'd cut that range in half--particularly with just Phase IIa data in hand. For the moment, rightly or wrongly, Strattera defines the expectable market for nonstimulant ADHD meds, and that would put it at the half billion per year potential level. The possibility of going higher exists, but a deal would probably account for that with milestones and royalties, not presuming it via higher upfronts. In other words, the eventual returns for Cortex have not changed, but they would be less front-loaded.

This is purely guesswork on my part.

NeuroInvestment